Adelaide, Australia – Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed PhD and NHMRC Fellow Patrick Hughes as R&D Manager Immunobiology.
Agilex Biolabs specializes in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments.
Agilex Biolabs, the only FDA-inspected lab of its type in the region, is located in Adelaide, South Australia in a science and biotech specialist hub.
Agilex Biolabs CEO Jason Valentine said:
“We are extremely pleased to have Patrick with his impressive scientific experience join our fast-growing bioanalytics company. He is an outstanding specialist research scientist who has been published in leading journals like JAMA, has authored and co-authored 29 papers, and is a senior lecturer at the Adelaide University Medical School.
“Agilex Biolabs stands out from the rest because of its talented team as well as state-of-the-art customized lab technology. Patrick is a perfect example of the caliber of talent we are consistently attracting to deliver world-class services for our clients.”
“By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.”
“Patrick joins us as we expand our labs by more than 30% to accommodate biotech demand from APAC and the USA.” Watch the Virtual Labs Tour Video Here
More than 38% of Agilex Biolabs’ biotech clients already come from the APAC region – primarily from China and South Korea.
APAC clients are particularly attracted by Agilex Biolabs’ FDA-inspected status, and the more than 40% rebate on clinical trial spend that applies in Australia.
Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).
Agilex also offers pharmacodynamics servicesthat include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
- Receptor occupancy
· Cytokine release assays (whole blood or PBMC stimulation assays) and
- PBMC assays and cellular mechanism of action assays (eg: ADCC)
The FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs from US, Europe and APAC.
“Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.”
About Agilex Biolabs https://www.agilexbiolabs.com/
Agilex Biolabs began as a group of academic scientists providing clinical trial and bioanalytical services to the local Australian pharmaceutical industry in the 1980’s, and has now grown into a global business for early phase clinical trials.
In our 20 years of performing regulated bioanalysis of small and large molecules, we have accelerated hundreds of preclinical and clinical trials around the world.
Today, our clients include many of the leading pharmaceutical and biotechnology companies in Asia, Europe and the USA.
Agilex Biolabs is built upon four core values that drive our performance:
- Scientific excellence and technological innovation
- Customer focus
- Data integrity and quality assurance
See us featured in Endpoints https://endpts.com/sp/partner-with-the-right-bioanalytics-firm-at-start-up-to-de-risk-drug-development/